In a study by Lingui et al., SPATA18 was found to be overexpressed in ccRCC tissues compared to normal ones and its expression was associated with a better prognosis in ccRCC patients, thus suggesting its potential use not only as a diagnostic and positive prognostic biomarker, but also in ccRCC treatment, given its tumor suppressive function [149]. The gene discussed is SPATA18; the disease is nonpapillary renal cell carcinoma.